Overview

Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
0
Participant gender:
Male
Summary
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wirral University Teaching Hospital NHS Trust
Collaborator:
Novartis
Treatments:
Androgens
Bicalutamide
Diphosphonates
Zoledronic Acid
Criteria
Inclusion Criteria:

- patients with locally advanced prostate cancer who progress from normal/ osteopenic
bone mineral density to osteoporosis while on LHRH agonists (LHRH Group). Also
patients who have been commenced on Bicalutamide due to osteoporosis at presentation
(Bicalutamide Group)

Exclusion Criteria:

- patients with elevated prostate specific antigen, any illness or medication that would
affect bone and mineral metabolism, previous bisphosphonate treatment, severe hepatic
or renal insufficiency.